NASDAQ$QSI

Quantum-Si Inc · Q3 2024 earnings

Q3 2024 earnings · · Investor relations

Briefing

Quantum-Si reported financial results for the third quarter ended September 30, 2024.

Quantum-Si reported revenue of $787,000 for the third quarter of 2024. The company is focusing on commercial execution and innovation, with new kits on track for launch in Q4. They anticipate not achieving their full year guided revenue range of $3.7 million to $4.2 million.

  • Reported revenue of $787,000 for the third quarter of 2024.
  • Liberate Bio integrated Platinum® Next-Generation Sequencing into their platform.
  • Todd Bennett appointed as Chief Commercial Officer, John Vieceli, Ph.D. as Chief Product Officer and Lindsay Thompson as Chief Human Resources Officer.
  • New library preparation kit and barcoding kit remain on track for launch before year end.

Headline financials

Total Revenue

$787K

Previous: $223K+252.9%
EPS

-$0.18

Previous: -$0.17-5.9%
Adjusted EBITDA

-$24.5M

Previous: -$22.6M-8.4%
Total Operating Expenses

$28.5M

No prior period
Adjusted Operating Expenses

$26M

No prior period
Research and Development

$16.2M

No prior period
SG&A

$12.3M

No prior period
Capital Expenditures

-$3.15M

Previous: -$4.88M+35.5%
Free Cash Flow

-$28.5M

Previous: -$29.6M+3.9%
Net Income

-$25.3M

Previous: -$24.7M-2.4%
Operating Income

-$28.1M

Previous: -$27.2M-3.4%
Gross Profit

$367K

Previous: $108K+239.8%
R&D Expense

$16.2M

Previous: $15M+7.9%
Stock-Based Comp

$2.41M

Previous: $1.14M+111.3%

Revenue & EPS history

Quantum-Si · Revenue · Quarterly

$787K

Q3 2024+252.9%vs Q3 2023
Beat estimate in 2 of 12 quarters(17%)
ActualEstimate

Forward guidance

Quantum-Si provided updated full year 2024 financial guidance for adjusted operating expenses and cash usage.

Tailwinds

  • Adjusted total operating expenses approximately $100 million.
  • Total cash usage approximately $92 million.
  • Cash runway into the second half of 2026.
  • Focus on commercial execution.
  • New kits expected to drive broader market adoption.

Headwinds

  • Potential shortfall in achieving full year guided revenue range of $3.7 million to $4.2 million.
  • Observed some lengthening of the sales cycle in the third quarter.
  • Uncertainties related to future performance and development.
  • Risks related to commercialization of products and services.
  • Competition with other companies in the proteomic analysis market.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2024

Historical avgQ3 2024

-4.1%

Avg return

Earnings day

-4.3%

Avg return

5 days after

+1.5%

Avg return

30 days after

39%

9 / 23 earnings

Positive

+14.5%

Q3 2023

Best reaction

-39.5%

Q2 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-4.5%-8.3%+1.0%
Q4 2025-4.3%-2.3%-21.1%
Q3 2025-8.5%-12.2%-20.0%
Q1 2025+0.0%-0.3%+12.2%
Q4 2024+6.2%-0.8%-10.8%
Q3 2024-20.8%-26.6%+81.0%
Q2 2024-2.8%-4.8%+4.5%
Q1 2024-5.6%+1.7%-17.8%
Q4 2023+6.3%-7.5%+13.2%
Q3 2023+14.5%+29.0%+26.6%
Q2 2023-39.5%-34.8%-31.9%
Q1 2023-13.5%-15.3%-1.8%
Q4 2022-12.5%-26.4%-27.8%
Q3 2022+3.2%+26.8%-7.6%
Q2 2022-6.0%+9.7%-14.4%
Q1 2022-14.9%-9.1%+3.0%
Q4 2019+6.2%-3.8%+12.5%
Q4 2021+6.8%-9.5%+13.1%
Q3 2021+1.2%+1.4%-21.5%
Q2 2021+1.9%+4.4%+14.2%
Q2 2020+1.9%+4.4%+14.2%
Q1 2021-7.6%-18.7%+28.5%
Q4 2020-1.1%+5.0%-13.8%
Q3 2020
Q1 2020

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro